Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Atorvastatin shown to decrease heart disease and stroke

11.10.2002


Atorvastatin shown to decrease heart disease and stroke in patients with hypertension and low cholesterol



A major European trial studying different blood pressure treatments and the effects of additional cholesterol lowering, announces today that it has stopped part of its trial earlier than expected because results collected already show a significant benefit to patients on one of its treatments.

It found that among 10,297 patients with hypertension and cholesterol levels lower than currently recommended for treatment, those given the cholesterol-lowering drug atorvastatin suffered significantly less heart attacks and strokes compared to those receiving the placebo treatment.


The International Steering Committee of the independent Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) have stopped the relevant part of the trial and informed fellow investigators, their patients and the regulatory authorities about the newly emerged results.

The rest of the trial, which compares different blood pressure treatment strategies, will continue unchanged.

"The trial shows that patients with high blood pressure but low cholesterol benefit clearly from taking a statin. It is too early to quantify the precise size of the effect, but we expect to see a reduction in heart attacks of about one-third among those taking a statin," say ASCOT study co-chairmen Björn Dahlöf from the Sahlgrenska University Hospital, Östra, Sweden and Peter Sever from Imperial College London, UK.

"However the ASCOT trial still continues and we wish to make it clear to all our patients that this new information does not mean they should stop the tablets they are taking. It is vital that all patients on the trial carry on with their treatment regimens," they add.

All patients will be recalled to visit their ASCOT doctors and will be examined again in the coming weeks

Members of ASCOT’s Data Safety Monitoring Board, who work independently of the trial investigators and are the only researchers permitted to look at the results of the five-year old trial while it is ongoing, reported their findings to the ASCOT International Steering Committee on 2 September 2002.

They described a highly significant reduction in the number of heart attacks and a significant reduction in the number of strokes experienced by those patients receiving atorvastatin compared to placebo.

As the size of the benefit exceeded the stopping rules for this part of the trial, the Data Safety Monitoring Board’s recommendations to close this section of the study were accepted by the ASCOT Steering Committee. This part of the study was formally closed on 1 October 2002 but data collection relating to it is expected to continue until the end of December 2002.

Further announcements about the results of the atorvastatin part of the trial will be made in 2003, with final results of the whole ASCOT study expected in 2004.

Patients were only eligible for the cholesterol lowering part of the trial if they had a blood cholesterol level of 6.5 mmol per litre or less - a significantly lower range of cholesterol levels than is usually treated by doctors. This part of the trial is specifically aimed to discover if a statin would confer additional protection against coronary heart disease in hypertensive patients with low cholesterol levels.

The other primary objective of ASCOT is to compare a new treatment strategy for hypertension against an old one, and discover which is better at preventing heart attacks.

The new treatment is a calcium channel blocker (amlodipine), to which in the majority of patients the angiotensin converting enzyme inhibitor, perindopril, is added to achieve the goal blood pressure. The older treatment is a beta blocker (atenolol), to which in the majority of patients a diuretic, bendrofluazide, is added to achieve goal blood pressure.

By May 2000, 19,342 patients had been entered on the trial and randomly selected to receive one of the two blood pressure lowering strategies. Out of the trial total 10,297 patients with low cholesterol were also randomised to receive either placebo or atorvastatin.

Patients in the trial are aged between 40 and 79 years old, with high blood pressure and have at least three other pre-specified cardiovascular risk factors.

The primary endpoint of the trial is either a heart attack from which the patient survives or death from coronary heart disease. A large number of other cardiovascular events including stroke are identified as secondary endpoints in the study.


###

Tony Stephenson | EurekAlert!
Further information:
http://www.ascotstudy.com

More articles from Health and Medicine:

nachricht Nitric oxide-scavenging hydrogel developed for rheumatoid arthritis treatment
06.06.2019 | Pohang University of Science & Technology (POSTECH)

nachricht Infants later diagnosed with autism follow adults’ gaze, but seldom initiate joint attention
24.05.2019 | Schwedischer Forschungsrat - The Swedish Research Council

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The hidden structure of the periodic system

The well-known representation of chemical elements is just one example of how objects can be arranged and classified

The periodic table of elements that most chemistry books depict is only one special case. This tabular overview of the chemical elements, which goes back to...

Im Focus: MPSD team discovers light-induced ferroelectricity in strontium titanate

Light can be used not only to measure materials’ properties, but also to change them. Especially interesting are those cases in which the function of a material can be modified, such as its ability to conduct electricity or to store information in its magnetic state. A team led by Andrea Cavalleri from the Max Planck Institute for the Structure and Dynamics of Matter in Hamburg used terahertz frequency light pulses to transform a non-ferroelectric material into a ferroelectric one.

Ferroelectricity is a state in which the constituent lattice “looks” in one specific direction, forming a macroscopic electrical polarisation. The ability to...

Im Focus: Determining the Earth’s gravity field more accurately than ever before

Researchers at TU Graz calculate the most accurate gravity field determination of the Earth using 1.16 billion satellite measurements. This yields valuable knowledge for climate research.

The Earth’s gravity fluctuates from place to place. Geodesists use this phenomenon to observe geodynamic and climatological processes. Using...

Im Focus: Tube anemone has the largest animal mitochondrial genome ever sequenced

Discovery by Brazilian and US researchers could change the classification of two species, which appear more akin to jellyfish than was thought.

The tube anemone Isarachnanthus nocturnus is only 15 cm long but has the largest mitochondrial genome of any animal sequenced to date, with 80,923 base pairs....

Im Focus: Tiny light box opens new doors into the nanoworld

Researchers at Chalmers University of Technology, Sweden, have discovered a completely new way of capturing, amplifying and linking light to matter at the nanolevel. Using a tiny box, built from stacked atomically thin material, they have succeeded in creating a type of feedback loop in which light and matter become one. The discovery, which was recently published in Nature Nanotechnology, opens up new possibilities in the world of nanophotonics.

Photonics is concerned with various means of using light. Fibre-optic communication is an example of photonics, as is the technology behind photodetectors and...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

 
Latest News

Novel communications architecture for future ultra-high speed wireless networks

17.06.2019 | Information Technology

Climate Change in West Africa

17.06.2019 | Earth Sciences

Robotic fish to replace animal testing

17.06.2019 | Ecology, The Environment and Conservation

VideoLinks
Science & Research
Overview of more VideoLinks >>>